Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
513 results about "Rat model" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Method for establishing obese rat animal model based on CRISPR (clustered regularly interspaced short palindromic repeat) gene knockout technology
InactiveCN103614415AImprove the level ofDeepen understanding of gene regulationVector-based foreign material introductionAnimal husbandryDiseaseLepr gene
The invention provides a method for establishing an obese rat animal model based on a CRISPR (clustered regularly interspaced short palindromic repeat) gene knockout technology. The method comprises the following steps: (1) establishing an Lep / Lepr gene knockout rat model; (2) carrying out the authentication and related analysis on the obese rat animal model; (3) evaluating the energy metabolism and the body fat rate of the obese rat animal model. According to the method, a CRISPR / Cas system is used for respectively or simultaneously knocking out Lep and LepR genes so as to obtain the rat model modified by a corresponding target gene, so that the understanding of gene regulation in the obesity morbidity process can be deepened, and the high-level animal model can be provided for the translational medicine and the new medicine research and development.
Owner:SUZHOU TONGSHAN BIO TECH
Tissue targeted complement modulators
InactiveUS20050265995A1Cell receptors/surface-antigens/surface-determinantsAntibody mimetics/scaffoldsEpitheliumWhole body
Systemic suppression of the complement system has been shown to be effective to treat inflammatory disease, yet at the potential cost of compromising host defense and immune homeostasis. Herein disclosed are methods for antigen-specific targeting of complement inhibitors that show that complement inhibitors targeted to the proximal tubular epithelium protect against tubulointerstitial injury and renal dysfunction in a rat model of nephrosis. It is shown that appropriate targeting of a systemically administered complement inhibitor to a site of disease markedy enhances efficacy and obviates the need to systemically inhibit complement. Additionally, it is shown by specifically inhibiting the terminal pathway of complement, that the membrane attack complex (MAC) plays a key role in proteinuria-induced tubulointerstitial injury, thus establishing the MAC as a valid target for pharmacological intervention in proteinuric disorders. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.
Owner:UNIVERSITY OF CHICAGO +1
Application of magnolia bark preparation in preparing medicine for treating diabetes and obesity
InactiveCN101015597AInhibitory activityGood hypoglycemic effectMetabolism disorderSolution deliveryDiseaseDiabetes model
The application of Magnolia officinalis preparation for the production of medicaments for treating diabetes and obesity belongs to the field of medicinal application. The Magnolia officinalis preparation is extracted from Magnolia officinalis by soaking in ethanol with magnolol and honokiol as main ingredients. The preparation has effects of in-vitro inhibiting the activity of protein-tyrosine phosphatase 1B (PTP1B) and reducing blood sugar level in rat model of type 2 diabetes. The preparation can be made into powder, pill, capsule, tablet, oral liquid and injection. It can be used for treating diabetes, obesity, and diseases related to PTP1B.
Owner:JILIN UNIV
Application of composite high-fat forage to construct non-alcoholic fatty liver disease rat model
The invention belongs to the field of animal experiment models, and discloses application of a composite high-fat forage to construct a non-alcoholic fatty liver disease rat model. The high-fat forage is composed of the following raw materials in percent by mass: 77.5% of a rat basic forage, 10% of egg, 10% of coconut oil, 2% of cholesterol, 0.5% of bile salt, and 500mg / kg / d of sodium valproate calculated according to the rat weight. After 8 weeks, rats all have typical non-alcoholic fatty live symptoms, and liver has a lot of fat accumulation along with inflammatory cell infiltration. The model establishing time is short, the success rate is high, and the composite high-fat forage is applicable to pathogenesis research induced by high-fat-diet combined medicines with liver-toxicity side effect, screening of related control measures and efficacy evaluation of treatment medicines.
Owner:NANJING GENERAL HOSPITAL NANJING MILLITARY COMMAND P L A +1
Method for preparing 2 type diabetes rat model
InactiveCN101095958AVerify authenticityVerify reliabilityFood processingAnimal feeding stuffHigh fatRat model
The invention relates to a method for preparing type-2 diabetes mouse model, which comprises following steps: using streptozocin to make the reaction of islets of pancreas beta cell of new-born mouse to sugar be reduced, injecting treptozocin to weaning mouse to injure islets of pancreas lightly, feeding mouse with high-sugar high-fat food to enable it resist to insulin, and getting type-2 diabetes mouse model. The type-2 diabetes mouse model is characterized by typical symptom of high fasting blood-glucose concentration, high insulinemia, reduced sugar-resistant property and insulin-resistant property. The time for preparing model is shortened and the success rate is high.
Owner:FIRST HOSPITAL OF SHANXI MEDICAL UNIV
Genetically Modified Rat Models for Cancer
ActiveUS20100287628A1Nucleic acid vectorVector-based foreign material introductionProgenitorHuman cancer
This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.
Owner:TRANSPOSAGEN BIOPHARM
Tissue targeted complement modulators
InactiveUS8454963B2Cell receptors/surface-antigens/surface-determinantsPeptide/protein ingredientsTissue targetingEpithelium
Systemic suppression of the complement system has been shown to be effective to treat inflammatory disease, yet at the potential cost of compromising host defense and immune homeostasis. Herein disclosed are methods for antigen-specific targeting of complement inhibitors that show that complement inhibitors targeted to the proximal tubular epithelium protect against tubulointerstitial injury and renal dysfunction in a rat model of nephrosis. It is shown that appropriate targeting of a systemically administered complement inhibitor to a site of disease markedy enhances efficacy and obviates the need to systemically inhibit complement. Additionally, it is shown by specifically inhibiting the terminal pathway of complement, that the membrane attack complex (MAC) plays a key role in proteinuria-induced tubulointerstitial injury, thus establishing the MAC as a valid target for pharmacological intervention in proteinuric disorders. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.
Owner:UNIVERSITY OF CHICAGO +1
Related ingredient combination with function of relaxing vessels in traditional Chinese medicine for reducing blood pressure
InactiveCN102727762AAvoid side effectsOrganic active ingredientsCardiovascular disorderVascular ringAdditive ingredient
The invention relates to the related ingredient combination with the function of relaxing vessels in traditional Chinese medicine for reducing blood pressure which is commonly used clinically. The invention utilizes modern traditional Chinese medicine theory and provides a related ingredient combination with definite ingredient, controllable quality and precise curative effect by animal model tests for reducing blood pressure. The related ingredient combination can be used for relaxing vessels, treating hypertension and improving hypertension complication. The commonly used traditional Chinese medicine relates to eucommia ulmoides, rhizoma gastrodiae, rhizoma chuanxiong, salviae miltiorrhizae, Astragalus mongholicus, root of kudzu vine, uncaria, radix stephaniae tetrandrae, red flower, radix scutellariae, selfheal, semen cassiae, dogbane leaf, hawthorn, radix achyranthis bidentatae, sophora flower, pseudo-ginseng, motherwort, chrysanthemum, lotus plumule, evodia, cape jasmine fruit, epimedium and caltrop which are included in Chinese Pharmacopoeia (2010 edition). The related ingredients are active ingredients which are extracted from single traditional Chinese medicine. Each traditional Chinese medicine provides one or several active ingredients. The combination study comprises the following steps of combining 2-6 active ingredients with different mechanisms in proportion, screening by utilizing rat thoracic aorta vascular rings and spontaneous hypertension rat models and determining the optimum combination proportion.
Owner:CHINA PHARM UNIV
External-used burn and scald treating medicine and its preparation
InactiveCN101254246APromote transdermal absorptionGood curative effectHydroxy compound active ingredientsDermatological disorderSecond-Degree BurnSide effect
The invention relates to a medicine for externally treating burn and scald, which is an ointment prepared from slough tissue of cultured second generation giant salamanders and subsequent generations thereof during growth period, radix glycyrrhizae, borneol, sinkiang arnebia root and sanguisorba officinalis. The inventive ointment is prepared from the radix glycyrrhizae extract, sinkiang arnebia root extract, sanguisorba officinalis extract and nanometer powder of giant salamander slough tissue that are obtained by modern biotechnology. The preparation method og the medicine comprises the steps of mixing according to a certain proportion, adding borneol and matrix that is made of Vaseline, vegetable oil, beeswax and anhydrous lanolin, homogenizing, and making into the ointment. The inventive medicine has the advantages of good therapeutic effect, quick action, good analgesic effect, short treatment course, no scar left, and no any toxic and side effects. Burn and scald rat model experiments prove that the inventive medicine shortens the healing time of the superficial second degree, the deep second degree and the third degree burns, there is no scar left on wound surface after healing for the superficial second degree and the deep second degree burns, and there is less scar left on wound surface after healing the third degree burn, with no need of skin grafting. The inventive medicine has better therapeutic effect than the prior medicines for treating burn and scald, and has very wide application prospect.
Owner:HUAZHONG UNIV OF SCI & TECH
Method for detecting, screening and identifying kidney-yang deficiency metabolism biomarkers
The invention relates to a method for detecting, screening and identifying metabolism biomarkers, in particular to a method for detecting, screening and identifying kidney-yang deficiency metabolism biomarkers. In order to solve the problem that in the prior art kidney-yang deficiency metabolism biomarkers cannot be determined, the method for detecting, screening and identifying kidney-yang deficiency metabolism biomarkers comprises the steps that a kidney-yang deficiency rat model is copied, a kidney-yang deficiency rat model is evaluated, a rat urine or blood QC sample is obtained through preparation; urine endogenous metabolites and blood endogenous metabolites are obtained; 33 urine biomarkers and 17 blood biomarkers are obtained through determination and identification of a rat urine metabolism counter track variation trend PCA score chat. The method is applied to the field of metabolism biomarker detection, screening and identification.
Owner:王喜军
Rat liver cancer model with different liver matrix hardness backgrounds and preparation method of rat liver cancer model
InactiveCN103191148AReduce mortalityAvoid source complex featuresInorganic active ingredientsAbnormal tissue growthRat liver
The invention relates to a rat liver cancer model with different liver matrix hardness backgrounds and a preparation method of the rat liver cancer model. The method for preparing the rat liver cancer model with different liver matrix backgrounds is characterized by specifically comprising the following steps of: after grouping the rats, injecting pure carbon tetrachloride to an abdominal region in a hypodermic manner; injecting a carbon tetrachloride-olive oil solution to the abdominal region in the hypodermic manner; detecting through a texture analyzer to form the rat model with different liver matrix hardness; taking liver cancer cells which are in-vitro cultured and grown well and injecting the liver cancer cells to the rat to form hypodermic liver cancer cells; in-situ planting the formed liver cancer tumor source to the rat model with different liver matrix hardness to obtain the rat liver cancer model with different liver matrix hardness backgrounds. The rat liver cancer model with different liver matrix hardness backgrounds can be used for well displaying liver cancer malignant pathological characteristics under the liver matrix hardness interference, simulating and reproducing pathological characteristics of clinical liver matrix hardening background liver cancer and solving the problems that an ideal experiment system, an animal model and the like are lacked in reaching the development of the liver cancer due to the liver matrix hardness changes.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV
Method for building spleen-deficiency chronic atrophic gastritis gastric precancerous lesions animal model
InactiveCN102648701ASyndrome of spleen deficiencyHave body temperatureIn-vivo testing preparationsAnimal husbandryNitrosoRat model
The invention relates to a method for building a spleen-deficiency chronic atrophic gastritis gastric precancerous lesions animal model. The method is based on the existing spleen-deficiency rat model and the existing chronic atrophic gastritis rat model and is used for building the animal model through united copy of free drinking of N-methyl-N '-nitro-N -nitrosoguanidine (MNNG) solution, irregular eating and purgation. The method comprises the following specific steps of: preparing 10mg / L MNNG storage solution by utilizing sterilized tap water, preparing 80 to 200 mug / mL MNNG solution in temporary use to substitute the drinking water to be drunk freely by the rats, and adopting the free drinking of MNNG as the beginning of the modeling; copying a spleen-deficiency syndrome through irregular eating and improved purgation way, feeding the rats on alternate days since the fifth week after the modeling, and utilizing qi-activating decoction for gavage in a dose of 1 to 3ml per rat every day in the seventh weak; and continuing the modeling for 12 weeks. The animal model built through the method is identical to or similar with the clinical syndrome and physical signs of middle-late lesions in chronic atrophic gastritis. After being verified in repeatedly modeling, the method has good repeatability and good stability. The built model is suitable for selecting traditional Chinese medicine for treating the chronic atrophic gastritis through a traditional Chinese medicine spleen treatment method.
Owner:潘华峰
Preparation method of rat model with hypertension complicated by hyperlipidemia
The invention aims to establish a rat model concerning pharmacodynamic screening, pharmological study and efficacy evaluation of a traditional Chinese medicine for treating concomitant hyperlipidemia and hypertension. On the basis of a hypertension rat model, model set rats are fed with high fat diet each day continuously for 2-6 weeks so as to create a hypertension complicated by hyperlipidemia model. The characteristic indicators of the model are mainly that the total cholesterol and triglyceride as well as low density lipoprotein cholesterin can be increased, and high-density lipoprotein cholesterol can be decreased while the blood pressure is increased.
Owner:ZHEJIANG CHINESE MEDICAL UNIVERSITY
Rat-pig intestinal epithelial cell integrated model established by lipopolysaccharide (LPS) stimulation
InactiveCN104031878AMitigation structureMitigation of structural changesMicrobiological testing/measurementVertebrate cellsRat intestineIn vivo
The invention discloses a rat-pig intestinal epithelial cell integrated model established by lipopolysaccharide (LPS) stimulation. Bacterial lipopolysaccharide (LPS) has a function in damaging intestinal epithelial barrier, and the integrated model disclosed by the invention aims at identifying whether an antimicrobial peptide Cathelicidin-BF (C-BF) derived from a snake has a protective effect on LPS-induced enteritidis or not. IPEC-J2 is an intestinal epithelial cell line isolated from the porcine jejunum segment and the porcine digestive system is very similar to the human digestive system. By in vivo rat model and in vitro porcine IPEC-J2 cell model, the protective effect of Cathelicidin-BF on impaired LPS-induced intestinal barrier function is tested. The test results show that the Cathelicidin-BF has protective effects on impaired LPS-induced intestinal barrier function and LPS-induced IPEC-J2 cell damage model.
Owner:ZHEJIANG UNIV
Transgenic rat as animal model for human huntingdon's disease
InactiveUS20070044162A1Lower metabolismReduced CMRGGlcBiocideGenetic material ingredientsHuntingtons choreaTherapeutic effect
Huntington's Disease (HD) is an autosomal-dominant inherited progressive neurodegenerative disease from the group of CAG repeat / polyglutamine diseases and is characterized by a triad of psychiatric alterations, dementia and motor dysfunction. On a sub-cellular level, a mutation with extended CAG tri-nucleotide repeats has been identified as the cause of HD. The therapeutic effects of certain substances can be tested on neurotoxically-induced or transgenic animal models with expanded CAG-repeats. In the present invention, transgenic rats were generated and characterized for human HD. Said rat model for human HD and other diseases of the CNS carries 51 CAG repeats under the control of a rat promoter and has a slow progressive neurological phenotype, closely reflecting human HD syndrome. The comparability of the rat model in relation to human HD is characterized by neuropathological, neuroradiological and neurochemical modifications accompanied by typical behavioral symptoms.
Owner:RIESS OLAF +1
Intermittent hypoxia big and small mice feeding cabin of loop track type
ActiveCN101584610AReduce consumptionLow costAnimal housingVeterinary instrumentsAnaerobic respirationNitrogen
The invention relates to an experimental animal feeding cabin, which is the big and small mice feeding cabin for simulating the symptom of intermittent anaerobic respiration of animal. One side of hypoxia feeding cabin is further connected with a buffering cabin formed from a closed cabin body and a feeding cage track such that the feeding cabin loading the big mouse is timed to stay between the hypoxia feeding cabin and the outside along the feeding cage track so as to simulate the big mouse model of SAS by the long-period intermittent breathing hypoxia gas. There is no need to timely and frequently discharge the nitrogen in the hypoxia feeding cabin, thus, the consumption quantity of the nitrogen is greatly reduced and the experiment cost is reduced by a wide margin.
Owner:WENZHOU MEDICAL UNIV
Traditional Chinese medicine preparation for treating senile dementia and preparation method thereof
InactiveCN101269179AGood curative effectImprovement of side effectsNervous disorderPlant ingredientsAnti stressSide effect
The invention discloses a traditional Chinese medicine formulation for curing senile dementia and a preparation method thereof. The traditional Chinese medicine formulation is made of ginseng, milk veteh, epimedium, fumitory, rhizoma gastrodiae, angelica, radid polygoni multflori preparata, sealwort and grassleaf sweelflag rhizome which are performed by an ethanol extracting technology and a poach technology. The traditional Chinese medicine formulation is ground by the theory of traditional Chinese medicine and adopts a scientific theory and an advanced technology to develop the traditional Chinese medicine formulation with good curative effect and fewer side effects and being used for curing the senile dementia. The experimental research shows that the traditional Chinese medicine formulation can improve the learning memory ability of an AD rat model. Meanwhile, the traditional Chinese medicine formulation can improve the antifatigue and anti-stress ability of an organism and has good curative effect on the kidney empty. In addition, the invention also provides an optimized preparation method suitable for the industrial production.
Owner:GUIYANG MEDICAL UNIVERSITY
Stem cell preparation for treating cirrhosis
InactiveCN102028970AImprove survivalBlocking and Reversing ProcessDigestive systemMammal material medical ingredientsWhole bodyUmbilical cord.placenta
The invention discloses a stem cell preparation for treating cirrhosis, which is prepared from stem cells from human umbilical cord placenta, normal saline containing seralbumin with concentration by volume being 0.5-5%, and low-molecular-weight heparin sodium with concentration being 50-701U / ml. When the stem cell preparation is transfused into a rat model with cirrhosis through a caudal vein, the effective dose of the stem cell preparation is 5*106 cells each time; and the effective dose of the stem cell preparation is 0.5-5*106 cells / kg each time when the stem cell preparation is transfused into a patient with cirrhosis through a peripheral vein. After applied to rats with cirrhosis and patients with cirrhosis, the stem cell preparation can obviously improve the survival rate of the rats with cirrhosis and the patients with cirrhosis, retard and invert a cirrhosis process, improve a whole state and a liver function state, and promote pathological recovery of liver, thereby developing a new way to cell therapy for treating cirrhosis.
Owner:UNION STEMCELL & GENE ENG +1
Pharmaceutical compositions comprising a tungsten salt (VI) for the treatment of neurodegenerative disorders, particularly alzheimer's disease and schizophrenia
InactiveCN101237875AReduce abnormal hyperphosphorylationLow priceHeavy metal active ingredientsNervous disorderMammalTherapeutic treatment
The present invention relates to a pharmaceutical composition for the treatment of neurodegenerative disorders, comprising an effective amount of a tungsten (VI) compound, preferably tungstate, and more preferably sodium tungstate (Na2WO4). The pharmaceutical composition of the present invention can be used for the preventive and / or therapeutic treatment of neurodegenerative disorders in mammals (including humans), and especially in the preventive and / or therapeutic treatment of Alzheimer's disease and schizophrenia. The effect of sodium tungstate dihydrate on tau phosphorylation was evaluated in rat models of insulin resistance and type 1 diabetes. Therapeutic treatment of Tau-associated diseases from the present invention includes several advantages: GSK3 inhibition; specificity, since it reduces abnormal hyperphosphorylation of tau caused by nerve-specific proteins; efficacy; lack of toxicity; and low price.
Owner:UNIV DE BARCELONA +1
Inula wissmannian extracts, preparation for same, and application of extracts in preparation of anti-inflammatory medicine
Owner:SHANGHAI JIAO TONG UNIV
Intermittent hypoxia big and small mice feeding cabin of linear track type
ActiveCN101584611AReduce consumptionLow costAnimal housingVeterinary instrumentsAnaerobic respirationNitrogen
The invention relates to an experimental animal feeding cabin, which is the big and small mice feeding cabin for simulating the symptom of intermittent anaerobic respiration of animal. One side of hypoxia feeding cabin is further connected with a buffering cabin formed from a closed cabin body and a feeding cage track such that the feeding cabin loading the big mouse is timed to stay between the hypoxia feeding cabin and the outside along the feeding cage track so as to simulate the big mouse model of SAS by the long-period intermittent breathing hypoxia gas. There is no need to timely and frequently discharge the nitrogen in the hypoxia feeding cabin, thus, the consumption quantity of the nitrogen is greatly reduced and the experiment cost is reduced by a wide margin.
Owner:WENZHOU MEDICAL UNIV
Genetically Modified Rat Models for Pharmacokinetics
The present invention provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to drug transport sensitivity or resistance drug transport resistance or sensitivity. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug transporter gene such as the Slc7a11 (NC_005101.2) gene, the Abcb1 (NC_005103.2) gene, etc. The present invention also provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to drug transport sensitivity or resistance drug transport resistance or sensitivity. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug transporter gene.
Owner:TRANSPOSAGEN BIOPHARM
System for determining functions of lower limb nerves and muscles of rat
InactiveCN102599921ARealize non-invasive experimentsAvoid errorsDiagnostic recording/measuringSensorsMuscle forceResearch Object
The invention relates to a system for determining functions of lower lib nerves and muscles of a rat. The system consists of a fixing device, a sensing device and a data processing device, the fixing device is connected with the sensing device via an electrical stimulation line and an output line, the sensing device is connected with the data processing device via a lead, the data processing device transmits nerve stimulation signals to the fixing device via the sensing device, the fixing device transmits received mechanical muscle force signals into the sensing device, the mechanical muscle force signals are converted and processed into electric signals via the sensing device, and the electric signals are transmitted into the data processing device, so that muscle force data are obtained. Compared with the prior art, the system provides a novel and reliable experimental platform, can digitally, quantitatively and dynamically monitor a single group of muscle force of a rat model, and accurately measures change of the muscle force of a research object at different time points.
Owner:TONGJI UNIV
Application of quercetin in preparing medicine for treating polycystic ovarian syndrome
ActiveCN103705501ANo nephrotoxicityLittle side effectsOrganic active ingredientsSexual disorderOperative woundSide effect
The invention relates to the technical field of traditional Chinese medicines, and provides application of quercetin in preparing a medicine for treating polycystic ovarian syndrome. A test is performed on a rat model with polycystic ovarian syndrome by adopting quercetin, and discovers that the quercetin has a remarkable treatment effect and can remarkably reverse insulin resistance. Quercetin does not have liver or kidney toxicity, is small in side effect, has a good clinical application prospect, does not have drug resistance, can avoid operative wounds, and obtains an excellent clinical effect in PCOS (polycystic ovary syndrome) treatment.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Pulsatile delivery composition for treating diabetes mellitus and preparation method thereof
The invention relates to a pulsatile delivery sustained-release tablet for treating diabetes mellitus and a preparation method thereof. The active components of the pulsatile delivery sustained-release tablet liraglutide, exenatide acetate or pramlintide acetate are respectively combined with insulin, and drugs are released according to a preset time. According to the pulsatile delivery sustained-release tablet, a polymer material is adopted as a coating film, the active components are combined with a swelling coating to serve as a tablet core, and medical auxiliaries are adopted. The dissolution percentage of the composition is further investigated, and an SD (sprague-dawley) diabetes rat model is used as a studying object to detect the fasting blood-glucose, 2hplasmaglucose, number of hypoglycemia times, dawn phenomenon indexes of the rat model, and the treatment effects are investigated.
Owner:SHENZHEN XINGYIN PHARML
Compound traditional Chinese medicinal effective component preparation for resisting alcoholic fatty liver disease and application thereof
ActiveCN103800352APromote reversalLowers triglyceride (TG) levelsOrganic active ingredientsDigestive systemChlorogenic acidRat model
The invention belongs to the field of traditional Chinese medicines, relates to a compound traditional Chinese medicinal effective component preparation for resisting alcoholic fatty liver disease and application thereof, and in particular relates to a compound traditional Chinese medicinal component preparation comprising geniposide and chlorogenic acid and application thereof. The compound preparation is prepared from geniposide and chlorogenic acid, and can be processed into clinical common preparations by a conventional method, including granules, tablets, capsules and other oral solid preparations. Animal experiments indicate that the compound preparation can remarkably reduce the content of triglyceride of liver tissues of a rat model, and reduce the degeneration degree of liver fat and liver damage degree. The effects of the compound preparation are superior to those of single component. The compound preparation can be used for improving the effect of resisting alcoholic fatty liver, effectively preventing development of non-alcoholic fatty liver, and can be used for treating and preventing non-alcoholic fatty liver, chronic liver damage and other symptoms.
Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
Application of baicalin in preparation of medicine for treating polycystic ovarian syndrome
ActiveCN103285021ALow toxicitySuitable for long-term useOrganic active ingredientsSexual disorderSide effectLiver and kidney
The invention discloses an application of baicalin in preparation of a medicine for treating polycystic ovarian syndrome. As shown in an in vivo experiment, the baicalin has obvious treatment effect on a polycystic ovarian syndrome rat model and can greatly reduce the high androgen level of the rat model, promote follicle maturity and induce ovulation; as shown in an in vitro experiment, the baicalin can inhibit the expression of androgen of a polycystic ovarian syndrome cell model. More importantly, the baicalin has small side effect and incomparable security while having no liver and kidney toxicity. Therefore, the baicalin can be used for preparing the medicine for treating polycystic ovarian syndrome and has a brilliant prospect.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Method for establishing CYP2D1 gene knockout rat model
InactiveCN105624191AReduce volumeSmall body fluid volumeNucleic acid vectorOxidoreductasesEnzyme digestionRat model
The invention relates to a method for establishing a CYP2D1 gene knockout rat model, and belongs to the technical field of transgenosis. The method comprises the steps of firstly determining a target point of a to-be-knocked gene and designing and synthesizing a primer sequence of the gene; inserting the primer sequence into a Cas9-gRNA-Bsal carrier subjected to enzyme digestion and performing amplification to obtain a target point sgRNA with a T7 promoter sequence; after in vitro transcription and purification, performing activity detection; micro-injecting active sgRNA and Cas9 RNA into a rat single-cell embryo to obtain a Founder rat; and after screening out a CYP2D1 gene knockout rat heterozygote, performing mating to obtain a homozygote individual, namely, a CYP2D1 gene knockout rat. The invention provides a preparation method replacing a mouse model with a P450 gene knockout rat model, so that a gene knockout technology is really fused in non-clinical safety evaluation of drugs and early toxicity of candidate drugs can be discovered.
Owner:JIANGSU UNIV
Compounds with thrombolytic activities and preparation methods and applications thereof
InactiveCN102241740AThrombolytic activityTetrapeptide ingredientsTripeptide ingredientsRat modelCerebral infarction
The invention discloses compounds with thrombolytic activities, preparation methods thereof and applications of the compounds as thrombolytic agents. The compounds disclosed by the invention are prepared by coupling or conjugating the 2 nitrogen of cyclized dopa respectively with H-Ala-Arg-Pro-Ala-Lys-OH, H-Pro-Ala-Lys-OH, H-Arg-Pro-Ala-Lys-OH, H-Gly-Arg-Pro-Ala-Lys-OH or H-Gln-Arg-Pro-Ala-Lys-OH. The thrombolytic activities of the compounds disclosed by the invention are evaluated by a rat model with carotid artery and jugular vein bypass catheter thrombosis, and shown by experimental results, the compounds disclosed by the invention have excellent thrombolytic activities and can be applied as thrombolytic agents clinically. The therapeutic actions of the compounds disclosed by the invention on cerebral infarction are further evaluated by a rat model with cerebral thrombosis, and shown by experimental results, the compounds disclosed by the invention all have excellent protective actions on brain tissues and can be applied as cerebral thrombolytic agents clinically.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Application of ethyl asterrate in preparation of anti-alzheimer medicine
InactiveCN103768075AEnhance memorySignificant anti-senile dementia effectSalicyclic acid active ingredientsNervous disorderStructural formulaRat model
The invention discloses application of ethyl asterrate in preparation of an anti-alzheimer medicine, and in particular relates to application of diphenyl ether compound ethyl asterrate shown in the structural formula (I) in inhibition of the activity of acetylcholine esterase and preparation of an anti-alzheimer medicine. Experiments prove that the ethyl asterrate can remarkably inhibit the activity of acetylcholine esterase, can remarkably improve the memory and space exploration capability of an alzheimer rat model caused by D-galactose and AlCl3, can be applied to preparation of the anti-alzheimer medicine, and indicates an excellent market application prospect.
Owner:YICHUN UNIVERSITY
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com